NHS England have recently proposed that NICE should take a more direct role in determining which pro...
Read moreEuropean payers have not considered biosimilars to be comparable to their reference products or full...
Read morePharmaceutical companies are able to charge significantly higher prices as these products are addres...
Read moreNew legislation has enabled AIFA to approve reimbursement for Avastin for off-label usage in the tre...
Read moreA recent Biosimilar pricing announcement of 72% discount of an anti-tumour necrosis factor blows con...
Read moreRecent initiatives indicate EU member states are heading for potential centralised drug procurement
Read moreRemap Consulting presents NICE's highly specialised technology methodology to EUCOPE
Read moreIf spending on Hepatitis C drugs exceeds a certain amount, drug manufacturers will be taxed
Read moreHow different perspectives on value and price can impact market access
Read more